Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. It manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, and xanthine derivatives in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
2019
2.1K+
LTM Revenue n/a
LTM EBITDA n/a
$786M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aarti Pharmalabs has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aarti Pharmalabs achieved revenue of $210M and an EBITDA of $45.1M.
Aarti Pharmalabs expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Aarti Pharmalabs valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $138M | $223M | $210M | n/a | XXX |
Gross Profit | $36.0M | $61.2M | $80.9M | XXX | XXX |
Gross Margin | 26% | 27% | 39% | XXX | XXX |
EBITDA | $22.8M | $39.6M | $45.1M | n/a | XXX |
EBITDA Margin | 17% | 18% | 22% | NaN% | XXX |
Net Profit | $14.1M | $22.3M | $25.0M | XXX | XXX |
Net Margin | 10% | 10% | 12% | XXX | XXX |
Net Debt | $29.5M | $21.9M | $27.8M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Aarti Pharmalabs's stock price is INR 720 (or $8).
Aarti Pharmalabs has current market cap of INR 65.3B (or $753M), and EV of INR 68.1B (or $786M).
See Aarti Pharmalabs trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$786M | $753M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Aarti Pharmalabs has market cap of $753M and EV of $786M.
Aarti Pharmalabs's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aarti Pharmalabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aarti Pharmalabs and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $786M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAarti Pharmalabs's NTM/LTM revenue growth is n/a
Aarti Pharmalabs's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $21K for the same period.
Over next 12 months, Aarti Pharmalabs's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aarti Pharmalabs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aarti Pharmalabs and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -6% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 14% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $21K | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aarti Pharmalabs acquired XXX companies to date.
Last acquisition by Aarti Pharmalabs was XXXXXXXX, XXXXX XXXXX XXXXXX . Aarti Pharmalabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Aarti Pharmalabs founded? | Aarti Pharmalabs was founded in 2019. |
Where is Aarti Pharmalabs headquartered? | Aarti Pharmalabs is headquartered in India. |
How many employees does Aarti Pharmalabs have? | As of today, Aarti Pharmalabs has 2.1K+ employees. |
Is Aarti Pharmalabs publicy listed? | Yes, Aarti Pharmalabs is a public company listed on BOM. |
What is the stock symbol of Aarti Pharmalabs? | Aarti Pharmalabs trades under 543748 ticker. |
When did Aarti Pharmalabs go public? | Aarti Pharmalabs went public in 2023. |
Who are competitors of Aarti Pharmalabs? | Similar companies to Aarti Pharmalabs include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
What is the current market cap of Aarti Pharmalabs? | Aarti Pharmalabs's current market cap is $753M |
What is the current revenue growth of Aarti Pharmalabs? | Aarti Pharmalabs revenue growth between 2023 and 2024 was -6%. |
Is Aarti Pharmalabs profitable? | Yes, Aarti Pharmalabs is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.